OBJECTIVE: To investigate peak expiratory flow rate (PEFR) and quality of life scores for their ability to predict exacerbations of asthma. PARTICIPANTS AND METHODS: We identified adults who received oral or inhaled asthma medications from 36 community drugstores. We administered the McMaster Asthma Quality of Life Questionnaire (AQLQ) and measured PEFR, defining "red zone" (highest risk) as a PEFR < 50% of each patient's expected value based on gender, age, and height. We identified asthma exacerbations (breathing-related emergency department visits and hospitalizations) within 4 and 12 months after enrollment and used proportional hazards regression to assess the ability of PEFR and AQLQ scores to predict exacerbations, controlling for clinical and demographic factors. RESULTS: A red zone PEFR was a significant univariable predictor of exacerbations within 12 months (hazard ratio [HR], 1.8; 95% confidence interval [CI], 1.1 to 3.0; P =.027). However, neither a red zone PEFR, the raw PEFR, or percent of predicted maximal PEFR were significantly predictive when controlling for AQLQ scores, clinical characteristics, or demographic data (P >.2). However, the 4 subscales of the AQLQ were each significant univariable and multivariable predictors of asthma exacerbations. For example, the overall AQLQ scale had a multivariable HR of 0.63 (95% CI, 0.46 to 0.87; P =.005) for exacerbations occurring within 4 months and 0.66 (95% CI, 0.54 to 0.82; P <.001) within 12 months. CONCLUSIONS: PEFR added no predictive information to that contained in AQLQ scores and clinical and demographic data. These results support the National Institutes of Health asthma guidelines' recommendation for routinely assessing symptoms but not PEFR.
OBJECTIVE: To investigate peak expiratory flow rate (PEFR) and quality of life scores for their ability to predict exacerbations of asthma. PARTICIPANTS AND METHODS: We identified adults who received oral or inhaled asthma medications from 36 community drugstores. We administered the McMaster Asthma Quality of Life Questionnaire (AQLQ) and measured PEFR, defining "red zone" (highest risk) as a PEFR < 50% of each patient's expected value based on gender, age, and height. We identified asthma exacerbations (breathing-related emergency department visits and hospitalizations) within 4 and 12 months after enrollment and used proportional hazards regression to assess the ability of PEFR and AQLQ scores to predict exacerbations, controlling for clinical and demographic factors. RESULTS: A red zone PEFR was a significant univariable predictor of exacerbations within 12 months (hazard ratio [HR], 1.8; 95% confidence interval [CI], 1.1 to 3.0; P =.027). However, neither a red zone PEFR, the raw PEFR, or percent of predicted maximal PEFR were significantly predictive when controlling for AQLQ scores, clinical characteristics, or demographic data (P >.2). However, the 4 subscales of the AQLQ were each significant univariable and multivariable predictors of asthma exacerbations. For example, the overall AQLQ scale had a multivariable HR of 0.63 (95% CI, 0.46 to 0.87; P =.005) for exacerbations occurring within 4 months and 0.66 (95% CI, 0.54 to 0.82; P <.001) within 12 months. CONCLUSIONS: PEFR added no predictive information to that contained in AQLQ scores and clinical and demographic data. These results support the National Institutes of Health asthma guidelines' recommendation for routinely assessing symptoms but not PEFR.
Authors: M Weinberger; M D Murray; D G Marrero; N Brewer; M Lykens; L E Harris; W M Tierney Journal: Am J Health Syst Pharm Date: 2001-05-01 Impact factor: 2.637
Authors: D M Mannino; D M Homa; C A Pertowski; A Ashizawa; L L Nixon; C A Johnson; L B Ball; E Jack; D S Kang Journal: MMWR CDC Surveill Summ Date: 1998-04-24
Authors: C J McDonald; J M Overhage; W M Tierney; P R Dexter; D K Martin; J G Suico; A Zafar; G Schadow; L Blevins; T Glazener; J Meeks-Johnson; L Lemmon; J Warvel; B Porterfield; J Warvel; P Cassidy; D Lindbergh; A Belsito; M Tucker; B Williams; C Wodniak Journal: Int J Med Inform Date: 1999-06 Impact factor: 4.046
Authors: M P Rutten-van Mölken; F Custers; E K van Doorslaer; C C Jansen; L Heurman; F P Maesen; J J Smeets; A M Bommer; J A Raaijmakers Journal: Eur Respir J Date: 1995-06 Impact factor: 16.671
Authors: Ann Chen Wu; Kelan Tantisira; Lingling Li; Brooke Schuemann; Scott T Weiss; Anne L Fuhlbrigge Journal: Chest Date: 2011-02-03 Impact factor: 9.410
Authors: Michael Schatz; Mitchell P Dombrowski; Robert Wise; Yinglei Lai; Mark Landon; Roger B Newman; Dwight J Rouse; Menachem Miodovnik; Mary Jo O'Sullivan; Steve N Caritis; Kenneth J Leveno; Ronald J Wapner; Deborah L Conway Journal: J Asthma Date: 2010-02 Impact factor: 2.515
Authors: Michael Schatz; David Mosen; Mark Kosinski; William M Vollmer; Elizabeth O'Connor; E Francis Cook; Robert S Zeiger Journal: Qual Life Res Date: 2006-10-11 Impact factor: 3.440